Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OPT009
MIFTS: 57

Optic Neuritis

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Optic Neuritis

About this section

MalaCards integrated aliases for Optic Neuritis:

Name: Optic Neuritis 12 74 52 36 54 6 43 15 17 71 32

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases Neuronal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1210
KEGG 36 H01717
ICD9CM 34 377.3
MeSH 43 D009902
NCIt 49 C84950
SNOMED-CT 67 66760008
ICD10 32 H46
UMLS 71 C0029134
Sources

Summaries for Optic Neuritis

About this section
KEGG : 36 Optic neuritis is a demyelinating inflammatory disease of the optic nerve that presents with an abrupt loss of vision. The majority of patients are between the ages of 20 and 50 years, with a mean age ranging from 30 to 35 years. It occurs more commonly in women than in men. The onset is usually with pain on eye movement in one eye and subacute visual loss. One-third of patients have a mildly edematous optic disc. The visual disturbance resolves in 95% of cases. Many cases of optic neuritis are associated with multiple sclerosis or neuromyelitis optica or can occur in isolation. Occasionally, optic neuritis can result from infectious processes involving the paranasal sinuses or occur in the course of a systemic viral infection. High-dosed intravenous methylprednisolone therapy speeds recovery but does not improve the final outcome. For patients judged to be at high risk of developing multiple sclerosis, immune prophylaxis with beta-interferon or glatiramer acetate is recommended.

MalaCards based summary : Optic Neuritis is related to autoimmune optic neuritis and neuromyelitis optica, and has symptoms including eye manifestations An important gene associated with Optic Neuritis is AQP4 (Aquaporin 4), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Prednisone and 4-Aminopyridine have been mentioned in the context of this disorder. Affiliated tissues include optic nerve which may cause a complete, eye and brain, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 An optic nerve disease that results in inflammation located in optic nerve which may cause a complete or partial loss of vision.

NIH Rare Diseases : 52 Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain. The condition may cause sudden, reduced vision in the affected eye(s). While the cause of optic neuritis is unknown, it has been associated with autoimmune diseases , infections, multiple sclerosis , drug toxicity and deficiency of vitamin B-12. Vision often returns to normal within 2-3 weeks without treatment. In some cases, corticosteroids are given to speed recovery. If known, the underlying cause should be treated.

Wikipedia : 74 Optic neuritis is a demyelinating inflammation of the optic nerve. It is also known as optic papillitis... more...

Sources

Related Diseases for Optic Neuritis

About this section

Diseases in the Optic Neuritis family:

Autoimmune Optic Neuritis

Diseases related to Optic Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 913)
# Related Disease Score Top Affiliating Genes
1 autoimmune optic neuritis 34.3 MOG MBP DPYSL5 CNTF AQP4
2 neuromyelitis optica 32.7 MOG MBP IL6 IL1B HLA-DRB1 GFAP
3 allergic encephalomyelitis 32.0 PLP1 MOG MBP
4 acute retrobulbar neuritis 31.6 MT-ND4 MBP AQP4
5 chickenpox 31.4 TNF IL6 IL10
6 optic nerve disease 31.4 TNF MT-ND4 MOG MBP MAG IL6
7 herpes zoster 31.2 TNF IL10 HLA-DRB1 CCR5
8 syphilis 31.2 TNF IL6 HLA-DRB1 CCR5
9 iridocyclitis 31.1 TNF IL6 IL10
10 chorioretinitis 31.1 TNF IL6 IL10
11 miller fisher syndrome 31.1 TNF MAG AQP4
12 lyme disease 31.0 TNF IL6 IL1B HLA-DRB1
13 measles 31.0 TNF IL6 IL1B HLA-DRB1 CXCL8
14 transverse myelitis 30.9 TNF MBP IL6 IL10 CXCL8 AQP4
15 neurosyphilis 30.9 IL10 CXCL8 CXCL10
16 cytomegalovirus retinitis 30.9 TNF IL10 HLA-DRB1 CCR5
17 posterior uveitis 30.9 TNF LTA IL6
18 internuclear ophthalmoplegia 30.8 MOG MBP DPYSL5 AQP4
19 guillain-barre syndrome 30.8 TNF MPZ MOG MBP MAG HLA-DRB1
20 wallerian degeneration 30.8 MPZ MAG CNTF
21 panuveitis 30.8 TNF IL6 IL10 HLA-DRB1
22 myelitis 30.8 TNF MOG MBP IL6 IL10 DPYSL5
23 myasthenia gravis 30.8 TNF PLP1 MBP LTA IL10
24 chronic inflammatory demyelinating polyradiculoneuropathy 30.8 MPZ MBP IL10 HLA-DRB1
25 spondylitis 30.7 TNF LTA IL6 IL10
26 macular retinal edema 30.7 TNF IL6 IL1B CXCL8
27 multifocal choroiditis 30.7 TNF IL10
28 rubella 30.7 TNF MOG IL6 IL1B IL10 HLA-DRB1
29 acute disseminated encephalomyelitis 30.7 MPZ MOG MBP IL1B IL10 HLA-DRB1
30 q fever 30.7 TNF IL6 IL1B IL10
31 mononeuropathy 30.7 TNF MPZ MAG
32 juvenile arthritis 30.7 IL6 IL10 CXCL8
33 exanthem 30.6 TNF IL6 IL1B IL10 CXCL8
34 scrub typhus 30.6 TNF IL1B IL10
35 sarcoidosis 1 30.6 TNF LTA IL1B HLA-DRB1 CXCL10 CCR5
36 aseptic meningitis 30.6 TNF IL1B IL10 CXCL8
37 meningitis 30.6 TNF IL6 IL1B IL10 CXCL8 AQP4
38 typhoid fever 30.5 TNF LTA IL6 IL1B HLA-DRB1
39 acquired immunodeficiency syndrome 30.5 TNF MBP IL6 IL1B IL10 CCR5
40 oligoarticular juvenile idiopathic arthritis 30.5 TNF HLA-DRB1 CCR5
41 cysticercosis 30.5 IL6 IL1B IL10
42 brucellosis 30.5 TNF IL6 IL10 CXCL8
43 polyradiculoneuropathy 30.5 MPZ MBP MAG IL10 HLA-DRB1
44 intracranial hypertension 30.5 TNF IL1B CXCL10 AQP4
45 retinal vascular disease 30.4 TNF IL6 IL1B CXCL8
46 crohn's colitis 30.4 TNF IL1B CXCL8
47 radiculopathy 30.4 IL6 IL10 CXCL8
48 purpura 30.4 TNF IL6 IL10
49 thyroiditis 30.4 TNF IL6 IL10
50 toxoplasmosis 30.4 TNF IL6 IL1B IL10 CCR5

Comorbidity relations with Optic Neuritis via Phenotypic Disease Network (PDN):


Hypertension, Essential Temporal Arteritis

Graphical network of the top 20 diseases related to Optic Neuritis:



Diseases related to Optic Neuritis
Sources

Symptoms & Phenotypes for Optic Neuritis

About this section

UMLS symptoms related to Optic Neuritis:


eye manifestations

MGI Mouse Phenotypes related to Optic Neuritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 AQP4 BDNF CCR5 CNTF DPYSL5 GFAP
2 cellular MP:0005384 10.21 BDNF CCR5 CNTF CXCL10 GFAP IL10
3 hematopoietic system MP:0005397 10.21 AQP4 CCR5 CNTF CXCL10 IL10 IL1B
4 homeostasis/metabolism MP:0005376 10.2 AQP4 BDNF CCR5 CNTF CXCL10 GFAP
5 growth/size/body region MP:0005378 10.18 AQP4 BDNF GFAP IL10 IL1B IL6
6 immune system MP:0005387 10.13 AQP4 CCR5 CNTF CXCL10 GFAP IL10
7 nervous system MP:0003631 9.89 AQP4 BDNF CCR5 CNTF CXCL10 DPYSL5
8 muscle MP:0005369 9.76 CCR5 CNTF GFAP IL10 IL6 MOG
9 vision/eye MP:0005391 9.36 AQP4 BDNF CCR5 GFAP IL10 IL6
Sources

Drugs & Therapeutics for Optic Neuritis

About this section

Drugs for Optic Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
4-Aminopyridine Approved Phase 4 504-24-5 1727
3
rituximab Approved Phase 4 174722-31-7 10201696
4 (T,G)-A-L Phase 4
5
Glatiramer Acetate Phase 4 147245-92-9 3081884
6 Antineoplastic Agents, Hormonal Phase 4
7 Potassium Channel Blockers Phase 4
8 Antineoplastic Agents, Immunological Phase 4
9 Adrenocorticotropic Hormone Phase 4
10 Melanocyte-Stimulating Hormones Phase 4
11 beta-Endorphin Phase 4
12
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
13
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
14
Interferon beta-1b Approved Phase 2, Phase 3 145155-23-3
15 Immunoglobulins, Intravenous Phase 3
16 Rho(D) Immune Globulin Phase 3
17 gamma-Globulins Phase 3
18 Complement System Proteins Phase 3
19 Hematinics Phase 3
20 Epoetin alfa Phase 3 113427-24-0
21 Fingolimod Hydrochloride Phase 2, Phase 3
22 Immunoglobulins Phase 3
23 Antibodies Phase 3
24 Vaccines Phase 3
25
Hydrochlorothiazide Approved, Vet_approved Phase 2 58-93-5 3639
26
Amiloride Approved Phase 2 2016-88-8, 2609-46-3 16231
27
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
28
Coal tar Approved Phase 1, Phase 2 8007-45-2
29
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
30
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
31
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
32
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
33
Simvastatin Approved Phase 2 79902-63-9 54454
34
Clemastine Approved, Investigational Phase 2 15686-51-8 26987
35
Histamine Approved, Investigational Phase 2 51-45-6 774
36
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
37
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
39
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
40 Sodium Chloride Symporter Inhibitors Phase 2
41 Antihypertensive Agents Phase 2
42 Amiloride, hydrochlorothiazide drug combination Phase 2
43 Pharmaceutical Solutions Phase 2
44 Antibodies, Monoclonal Phase 2
45 Sodium Channel Blockers Phase 2
46 diuretics Phase 2
47 Diuretics, Potassium Sparing Phase 2
48 Anticonvulsants Phase 2
49 polysaccharide-K Phase 1, Phase 2
50 Alkylating Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
2 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4 Prednisolone
3 Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10) Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
4 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Recruiting NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV methylprednisolone (steroids)
5 Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances Recruiting NCT02849782 Phase 4 Fampridine
6 Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE): a Prospective, Multicenter, Open-label, Follow-up Clinical Trial Active, not recruiting NCT04256252 Phase 4 Rituximab
7 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4 ACTHAR;ACTHAR;ACTHAR;ACTHAR
8 Optical Coherence Tomography as a Measure of Neuroprotection in Patients With Relapsing-Remitting Multiple Sclerosis Receiving Natalizumab or Interferon Beta-1a Withdrawn NCT00771043 Phase 4 TYSABRI and AVONEX
9 An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
10 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study Unknown status NCT02220244 Phase 3 MD1003 100mg capsule
11 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
12 Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial Unknown status NCT00261326 Phase 3 simvastatin;placebo
13 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Completed NCT01962571 Phase 3 Erythropoietin alfa;Placebo
14 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
15 Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
16 Recovery of Demyelinating Optic Neuritis After Treatment With Equivalent High Doses of Oral vs. Intravenous Corticosteroids: a Randomized Single Blinded Clinical Trial Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
17 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
18 Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
19 Effects of Dalfampridine on Cognition in Multiple Sclerosis Completed NCT02006160 Phase 2, Phase 3 dalfampridine;placebo
20 A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) Recruiting NCT04201262 Phase 3
21 A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder Recruiting NCT04155424 Phase 2, Phase 3 Eculizumab
22 A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Active, not recruiting NCT02003144 Phase 3
23 Erythropoietin in Methanol Associated Optic Neuropathy Active, not recruiting NCT02376881 Phase 3 Erythropoietin
24 Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis Terminated NCT01647880 Phase 2, Phase 3 Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
25 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO) Terminated NCT01892345 Phase 3 Eculizumab;Placebo
26 The Investigation Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2 Vitamin D;Vitamin D withheld
27 Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial Unknown status NCT02976766 Phase 2 Gypenosides;Placebo
28 A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
29 Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
30 A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
31 Hyperbaric Oxygen Treatment of Mandibular Osteoradionecrosis. A Randomized Clinical Study Unknown status NCT00760682 Phase 2
32 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis Completed NCT01721161 Phase 2 Placebo
33 A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis Completed NCT01802489 Phase 2 Amiloride;Placebo
34 Visual Reconstitution Therapy After Optic Neuritis Completed NCT01274702 Phase 2
35 a Phase II Double Blind, Randomized, Placebo Controlled Trial of Effect of Phenytoin on the Ganglion Cell Inner Plexiform Layer (GCIPL) Thickness and Visual Field in Patients With a First Episode of Acute Optic Neuritis Completed NCT02939937 Phase 2 Phenytoin;placebo
36 A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis Completed NCT01451593 Phase 2 Phenytoin;Placebo
37 A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201 Completed NCT02657915 Phase 2 Placebo;BIIB033 100mg/Kg
38 Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT) Completed NCT00355095 Phase 2 Erythropoietin
39 Autologous Adult Human Mesenchymal Stem Cells: a Neuroprotective Therapy for Multiple Sclerosis Completed NCT00395200 Phase 1, Phase 2
40 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
41 Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD) Completed NCT03062579 Phase 1, Phase 2 Tocilizumab
42 Trial of High Dose Immunosuppressive Therapy With Hematopoietic Stem Cell Support in Devic's Disease Completed NCT00787722 Phase 1, Phase 2 Cyclophosphamide;G-CSF;rATG;Mesna;Rituximab;Methylprednisolone
43 A Phase II Trial of High-Dose Vitamin D Induction in Optic Neuritis (VitaDON 2) Recruiting NCT03302585 Phase 2 Vitamin D3;Placebo/Standard of Care Vitamin D3
44 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis Recruiting NCT02521311 Phase 2 Clemastine;Placebo
45 Treatment of Optic Neuropathies Using Autologous Bone-Marrow Derived Clusters of Differentiation (CD) 34+, 133+, and 271+ Stem Cells: A Pilot Study Recruiting NCT02638714 Phase 1, Phase 2
46 A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis Recruiting NCT03536559 Phase 2 CNM-Au8;Placebo
47 An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study Recruiting NCT03465111 Phase 2 ACTH (adrenocorticotropic hormone) gel
48 A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage Recruiting NCT03896217 Phase 2 Simvastatin
49 A 48-week, Double-blind, Randomized, Multi-center, Parallel-group Study Comparing Structural Changes in the Retina and Evolution of Visual Function After Immediate Versus Delayed Treatment With Fingolimod in Patients With Acute Demyelinating Optic Neuritis Terminated NCT01757691 Phase 2 Fingolimod 0.5mg/daily;Placebo
50 Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON) Terminated NCT01073813 Phase 2 Minocycline

Search NIH Clinical Center for Optic Neuritis

Cochrane evidence based reviews: optic neuritis

Sources

Genetic Tests for Optic Neuritis

About this section
Sources

Anatomical Context for Optic Neuritis

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Optic Neuritis:

19
Optic Nerve Which May Cause A Complete

MalaCards organs/tissues related to Optic Neuritis:

40
Eye, Brain, Testes, Retina, Spinal Cord, T Cells, Lung
Sources

Publications for Optic Neuritis

About this section

Articles related to Optic Neuritis:

(show top 50) (show all 5530)
# Title Authors PMID Year
1
Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. 61 54
20019228 2010
2
Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. 61 54
19917985 2009
3
Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. 54 61
19140826 2009
4
Neuromyelitis optica pathogenesis and aquaporin 4. 61 54
18510734 2008
5
A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. 54 61
18509235 2008
6
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. 61 54
12838519 2003
7
Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. 54 61
12732654 2003
8
Multiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis. 61 54
11985632 2002
9
Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD1a. 54 61
10618693 1999
10
Augmented expression of tumour necrosis factor-alpha and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. 61 54
8624683 1996
11
Acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system. 54 61
8526468 1995
12
PCR typing of two short tandem repeat (STR) structures upstreams of the human myelin basic protein (MBP) gene; the genetic susceptibility in multiple sclerosis and monosymptomatic idiopathic optic neuritis in Danes. 61 54
9345452 1995
13
Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. 54 61
7532318 1995
14
Optic neuritis and multiple sclerosis: the T cell repertoires to myelin proteins and MBP peptides change with time. 54 61
7524258 1994
15
Autoimmune T cell repertoire in optic neuritis and multiple sclerosis: T cells recognising multiple myelin proteins are accumulated in cerebrospinal fluid. 61 54
7515411 1994
16
Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. 61 54
7510098 1994
17
Optic neuritis is associated with myelin basic protein and proteolipid protein reactive cells producing interferon-gamma, interleukin-4 and transforming growth factor-beta. 54 61
7507500 1994
18
Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. 54 61
7510787 1994
19
Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. 61 54
7513391 1993
20
T cells recognizing multiple peptides of myelin basic protein are found in blood and enriched in cerebrospinal fluid in optic neuritis and multiple sclerosis. 61 54
7680141 1993
21
Acute optic neuritis associated with immunization with the CNS myelin proteolipid protein. 61 54
1373123 1992
22
Neuroprotection mediated by natural products and their chemical derivatives. 61
32394948 2020
23
Altered fovea in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. 61
32576604 2020
24
Optic neuritis in German children: clinical findings and association with multiple sclerosis. 61
32274587 2020
25
Optic nerve atrophy and whole and regional brain atrophy in Leber's hereditary optic neuropathy with multiple sclerosis-like disease with m.11778G>A mutation. 61
32387972 2020
26
Papulonecrotic tuberculid with optic neuritis. 61
32445311 2020
27
Is Asian type MS an MS phenotype, an NMO spectrum disorder, or a MOG-IgG related disease? 61
32361664 2020
28
Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors. 61
32461353 2020
29
Diagnostic features of initial demyelinating events associated with serum MOG-IgG. 61
32442864 2020
30
Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study. 61
32424064 2020
31
Association of body mass index with longitudinal rates of retinal atrophy in multiple sclerosis. 61
32297826 2020
32
Comparing Colored and White-Black Visual Evoked Potentials in Multiple Sclerosis Patients. 61
32550773 2020
33
Acute Inflammatory Optic Neuritis Associated with a Self-Taper of Oral Prednisone in a Patient Taking Adalimumab. 61
32395171 2020
34
Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside. 61
32533450 2020
35
Toric Lentis Mplus intraocular lens opacification: A case report. 61
32292834 2020
36
Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. 61
32179483 2020
37
The relationship between aquaporin-4 antibody status and visual tract integrity in neuromyelitis optica spectrum disorders: A visual evoked potential study. 61
32575026 2020
38
Possible link of genetic variants to autoimmunity in GAD-antibody-associated neurological disorders. 61
32388243 2020
39
Cerebral venous thrombosis presenting with isolated vision loss misdiagnosed as optic neuritis. 61
31792762 2020
40
Recurrent Bilateral Myelin Oligodendrocyte Glycoprotein Antibody Optic Neuritis in a Leber Hereditary Optic Neuropathy Carrier. 61
31842145 2020
41
New actors in optic neuritis pathogenesis: An Editorial for "Influence of retinal NMDA receptor activity during autoimmune optic neuritis" on page 693. 61
32162696 2020
42
About 3 cases of post-acute retinopathy of chikungunya fever. 61
32505386 2020
43
Bruch's membrane opening minimum rim width provides objective differentiation between glaucoma and non-glaucomatous optic neuropathies. 61
32574771 2020
44
Influence of retinal NMDA receptor activity during autoimmune optic neuritis. 61
32031240 2020
45
Neurological Adverse Effects Associated With Anti-tumor Necrosis Factor Alpha Antibodies in Pediatric Inflammatory Bowel Diseases. 61
32443044 2020
46
A case of MOG encephalomyelitis with T- cell lymphoma. 61
32155461 2020
47
Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. 61
32482845 2020
48
Bartonella neuroretinitis (cat-scratch disease). 61
32546517 2020
49
Herpes Simplex Virus 2 Meningoencephalitis-Associated Bilateral Optic Neuritis and Radiculitis. 61
32395172 2020
50
Toxocariasis of the Nervous System. 61
31960218 2020
Sources

Variations for Optic Neuritis

About this section

ClinVar genetic disease variations for Optic Neuritis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MT-ND4 NC_012920.1:m.11443A>CSNV Uncertain significance 523305 rs1556423952 MT:11443-11443 MT:11443-11443
Sources

Expression for Optic Neuritis

About this section
Search GEO for disease gene expression data for Optic Neuritis.
Sources

Pathways for Optic Neuritis

About this section

Pathways related to Optic Neuritis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.84 TNF LTA IL6 IL1B IL10 CXCL8
2
PEDF Induced Signaling 63
Show member pathways
 13.71 TNF LTA IL6 IL1B IL10 CXCL8
3
Akt Signaling 63
Show member pathways
 13.44 TNF LTA IL6 IL1B IL10 CXCL8
4
PAK Pathway 63
Show member pathways
 13.32 TNF LTA IL6 IL1B IL10 CXCL8
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.3 TNF LTA IL6 IL1B IL10 HLA-DRB1
6
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.07 TNF IL6 IL1B IL10 CXCL8 CXCL10
7
Allograft rejection 1 36
Show member pathways
 12.88 TNF LTA IL6 IL1B IL10 HLA-DRB1
8
Measles 36
Show member pathways
 12.86 TNF IL6 IL1B HLA-DRB1 CXCL8 CXCL10
9
Herpes simplex virus 1 infection 36
12.8 TNF LTA IL6 IL1B HLA-DRB1
10
NF-KappaB Family Pathway 63
Show member pathways
 12.72 TNF LTA IL6 IL1B BDNF
11
T cell receptor signaling pathway 36
Show member pathways
 12.63 TNF IL6 IL1B IL10 CCR5
12
Th17 cell differentiation 36
Show member pathways
 12.62 TNF IL6 IL1B IL10 HLA-DRB1
13
JAK-STAT signaling pathway 36
Show member pathways
 12.48 IL6 IL10 GFAP CNTF CCR5
14
IL-17 Family Signaling Pathways 64
Show member pathways
 12.39 TNF IL6 IL1B CXCL8 CXCL10
15
Human T-cell leukemia virus 1 infection 36
12.35 TNF LTA IL6 HLA-DRB1
16
Salmonella infection (KEGG) 36
12.32 TNF IL6 IL1B CXCL8
17
Toxoplasmosis 36
Show member pathways
 12.31 TNF IL1B IL10 HLA-DRB1 CCR5
18
Pathogenic Escherichia coli infection 36
12.28 TNF IL6 IL1B CXCL8
19
Tuberculosis 36
12.28 TNF IL6 IL1B IL10 HLA-DRB1
20
NOD-like receptor signaling pathway 36
12.26 TNF IL6 IL1B CXCL8
21
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.25 TNF LTA IL6 IL10 CXCL8 CXCL10
22
C-type lectin receptor signaling pathway 36
Show member pathways
 12.23 TNF IL6 IL1B IL10
23
Bacterial infections in CF airways 22
Show member pathways
 12.23 TNF IL6 IL1B CXCL8 CXCL10
24
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.21 TNF LTA IL6 IL1B IL10 CXCL8
25
Yersinia infection 36
12.05 TNF IL6 IL1B IL10 CXCL8
26
Interleukin-4 and 13 signaling 65
12.02 TNF IL6 IL1B IL10 CXCL8
27
TNF signaling pathway 36
12 TNF LTA IL6 IL1B CXCL10
28
NF-kappa B signaling pathway 36
11.99 TNF LTA IL1B CXCL8
29
AGE-RAGE signaling pathway in diabetic complications 36
11.97 TNF IL6 IL1B CXCL8
30
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.97 TNF PLP1 IL6 IL1B IL10 CXCL8
31
Hematopoietic cell lineage 36
11.96 TNF IL6 IL1B HLA-DRB1
32
IL27-mediated signaling events 1
Show member pathways
 11.96 TNF LTA IL6 IL1B IL10
33
Amoebiasis 36
11.92 TNF IL6 IL1B IL10 CXCL8
34
Innate Lymphoid Cells Differentiation 64
11.85 TNF LTA IL1B IL10
35
Neural Stem Cells and Lineage-specific Markers 64
11.85 MOG GFAP CNTF BDNF
36
Rheumatoid arthritis 36
11.84 TNF IL6 IL1B HLA-DRB1 CXCL8
37
TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions 64
Show member pathways
 11.81 TNF LTA BDNF
38
Dendritic Cells Developmental Lineage Pathway 64
11.81 TNF IL6 IL1B IL10
39
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.72 TNF IL6 IL1B CXCL8
40
Lung fibrosis 1
11.72 TNF IL6 IL1B CXCL8
41
Pertussis 36
11.71 TNF IL6 IL1B IL10 CXCL8
42
MECP2 and Associated Rett Syndrome 1
11.67 MBP MAG BDNF
43
Legionellosis 36
11.66 TNF IL6 IL1B CXCL8
44
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.52 TNF IL6 IL1B
45
Malaria 36
11.5 TNF IL6 IL1B IL10 CXCL8
46
African trypanosomiasis 36
11.42 TNF IL6 IL1B IL10
47
Spinal Cord Injury 1
11.4 TNF MBP MAG IL6 IL1B GFAP
48
IL-10 Pathway 63
11.37 TNF IL6 IL1B IL10
49
Development and heterogeneity of the ILC family 1
11.36 TNF IL6 IL1B
50
Antifolate resistance 36
11.35 TNF IL6 IL1B
Sources

GO Terms for Optic Neuritis

About this section

Cellular components related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 TNF LTA IL6 IL1B IL10 CXCL8
2 extracellular space GO:0005615 9.65 TNF LTA IL6 IL1B IL10 HLA-DRB1
3 external side of plasma membrane GO:0009897 9.63 TNF MOG HLA-DRB1 CXCL10 CCR5 AQP4
4 astrocyte end-foot GO:0097450 9.37 GFAP AQP4
5 compact myelin GO:0043218 9.26 MBP MAG
6 myelin sheath GO:0043209 8.92 PLP1 MPZ MBP MAG

Biological processes related to Optic Neuritis according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.11 LTA IL6 IL1B IL10 HLA-DRB1 DPYSL5
2 positive regulation of gene expression GO:0010628 10.07 TNF PLP1 IL6 IL1B CNTF
3 cell-cell signaling GO:0007267 9.99 LTA IL1B CXCL10 CCR5
4 response to lipopolysaccharide GO:0032496 9.93 LTA IL1B IL10 CXCL10
5 defense response GO:0006952 9.9 TNF CXCL8 CXCL10 CCR5
6 negative regulation of neuron apoptotic process GO:0043524 9.89 MAG IL10 CNTF BDNF
7 inflammatory response GO:0006954 9.87 TNF PLP1 IL6 IL1B CXCL8 CXCL10
8 neutrophil chemotaxis GO:0030593 9.85 IL1B CXCL8 CXCL10
9 chemokine-mediated signaling pathway GO:0070098 9.85 CXCL8 CXCL10 CCR5
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 TNF IL6 CNTF
11 response to glucocorticoid GO:0051384 9.84 TNF IL6 IL10
12 positive regulation of DNA-binding transcription factor activity GO:0051091 9.84 TNF IL6 IL1B IL10
13 humoral immune response GO:0006959 9.82 TNF LTA IL6
14 myelination GO:0042552 9.82 PLP1 MPZ MBP
15 positive regulation of interleukin-6 production GO:0032755 9.81 TNF IL6 IL1B
16 cellular response to lipopolysaccharide GO:0071222 9.8 TNF IL6 IL1B IL10 CXCL8 CXCL10
17 positive regulation of interferon-gamma production GO:0032729 9.78 TNF LTA IL1B
18 positive regulation of interleukin-6 secretion GO:2000778 9.76 TNF MBP IL1B
19 cytokine-mediated signaling pathway GO:0019221 9.76 TNF IL6 IL1B IL10 CXCL8 CXCL10
20 positive regulation of JAK-STAT cascade GO:0046427 9.72 TNF IL6 IL10
21 negative regulation of neurogenesis GO:0050768 9.7 TNF IL6 IL1B
22 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.68 MBP IL10
23 response to molecule of bacterial origin GO:0002237 9.68 IL10 CXCL8
24 negative regulation of lipid storage GO:0010888 9.67 TNF IL6
25 regulation of establishment of endothelial barrier GO:1903140 9.66 TNF IL1B
26 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
27 axon ensheathment GO:0008366 9.65 PLP1 MBP
28 leukocyte chemotaxis GO:0030595 9.65 IL10 CXCL8 CXCL10
29 negative regulation of cytokine production involved in immune response GO:0002719 9.63 TNF IL10
30 astrocyte activation GO:0048143 9.63 TNF IL1B CNTF
31 positive regulation of fever generation GO:0031622 9.62 TNF IL1B
32 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.62 TNF LTA
33 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 TNF IL10
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 TNF IL1B IL10
35 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
36 positive regulation of neuroinflammatory response GO:0150078 9.58 TNF IL6 IL1B
37 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.57 TNF IL1B
38 receptor biosynthetic process GO:0032800 9.56 TNF IL10
39 regulation of retinal cell programmed cell death GO:0046668 9.51 CNTF BDNF
40 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.49 TNF LTA
41 positive regulation of glial cell proliferation GO:0060252 9.35 TNF LTA IL6 IL1B GFAP
42 immune response GO:0006955 9.32 TNF MBP LTA IL6 IL1B IL10

Molecular functions related to Optic Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 MOG MAG LTA CXCL10 BDNF
2 structural constituent of myelin sheath GO:0019911 9.32 PLP1 MBP
3 interleukin-6 receptor binding GO:0005138 9.26 IL6 CNTF
4 growth factor activity GO:0008083 9.26 IL6 IL10 CNTF BDNF
5 cytokine activity GO:0005125 9.23 TNF LTA IL6 IL1B IL10 CXCL8
Sources

Sources for Optic Neuritis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....